Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Información

DOI:
https://doi.org/10.1002/14651858.CD013068Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 07 julio 2018see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud digestiva

Copyright:
  1. Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Anne S Strik

    Correspondencia a: Academic Medical Center, Amsterdam, Netherlands

    [email protected]

  • Erwin Dreesen

    University of Leuven, Leuven, Belgium

  • Mark Samaan

    Academic Medical Center, Amsterdam, Netherlands

  • Krisztina Gecse

    Academic Medical Center, Amsterdam, Netherlands

  • Mijntje Matheeuwsen

    Academic Medical Center, Amsterdam, Netherlands

  • Sophie Berends

    Academic Medical Center, Amsterdam, Netherlands

  • Geert D'Haens

    Academic Medical Center, Amsterdam, Netherlands

Contributions of authors

Draft the protocol: Anne Strik and Krisztina Gecse
Develop and run the search strategy: Anne Strik and Krisztina Gecse
Obtain copies of studies: Anne Strik
Select which studies to include (2 people): Anne Strik and Erwin Dreesen
Extract data from studies (2 people): Anne Strik and Erwin Dreesen
Enter data into RevMan: Anne Strik
Carry out the analysis: Anne Strik, Krisztina Gecse, Mark Samaan and Erwin Dreesen
Interpret the analysis: Anne Strik, Krisztina Gecse, Mark Samaan, Erwin Dreesen and Geert D’Haens
Draft the final review: All
Check correct use of grammar: All
Update the review: Anne Strik

Sources of support

Internal sources

  • Academic Medical Center Amsterdam, Netherlands.

External sources

  • The Cochrane Collaboration, Other.

Declarations of interest

Anne S Strik: None known.

Mark Samaan reports having received consultancy fees from Hospira, Takeda and Janssen; lecture fees from MSD, Janssen, Falk, Takeda and Tillots; and travel support from Takeda and Tillots.

Krisztina Gecse reports having received consultancy fees from Amgen, Abbvie, Boehringer Ingelheim, Ferring, Hospira, Immunic AG, MSD, Pfizer, Sandoz, Takeda and Tigenix.

Mijntje Matheeuwsen: None known.

Erwin Dreesen: None known.

Sophie Berends: None known

Geert D'Haens reports having received consultancy fees from AbbVie, Boehringer Ingelheim GmbH, Jansen Biologics, Merck Sharp and Dohme Corp, Mitsubishi Tanabe Pharma, Pfizer, Sandoz, Takeda, lecture fees from AbbVie, Jansen Biologics, Merck Sharp and Dohme Corp, Pfizer, Takeda and research grants from Abbott Laboratories/Abbvie, Jansen Biologics, MSD, Takeda.

Acknowledgements

Funding for the Cochrane IBD Group (May 1, 2017 ‐ April 30, 2022) has been provided by Crohn's and Colitis Canada (CCC).

The authors thank John MacDonald and Tran Nguyen for their help with the development of the protocol.

This project was not funded.

Version history

Published

Title

Stage

Authors

Version

2018 Jul 07

Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab

Protocol

Anne S Strik, Erwin Dreesen, Mark Samaan, Krisztina Gecse, Mijntje Matheeuwsen, Sophie Berends, Geert D'Haens

https://doi.org/10.1002/14651858.CD013068